Inogen (NASDAQ:INGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Inogen (NASDAQ:INGN) released its earnings results on Tuesday, February 24th. The medical technology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.10, Zacks reports. Inogen had a negative net margin of 6.52% and a negative return on equity of 11.56%. The firm had revenue of $81.72 million for the quarter, compared to the consensus estimate of $82.00 million.

Here are the key takeaways from Inogen’s conference call:

• Returned to Adjusted EBITDA profitability with positive Adjusted EBITDA of $2.7M in 2025, an adjusted net loss narrowed to $8M, and $120.9M in cash with no debt, giving the company financial flexibility to invest and repurchase stock.
• Expanded product portfolio and TAM — launches of Simeox, Voxi 5, and Aurora CPAP masks plus a new patient portal broaden Inogen from a POC company to a multi-product respiratory platform and increase estimated TAM from ~$400M to ~$3.4B.
• Near-term demand/timing issues: several large customer orders shifted from Q4 into H1 2026, U.S. sales declined 5.1% in Q4, rental revenue fell, and gross margin contracted (~220 bps) due to an unfavorable channel mix.
• Share repurchase and forward guidance — Board authorized a $30M buyback and management guided to roughly 6% revenue growth for 2026 with continued positive Adjusted EBITDA and a longer-term goal of ?10% Adjusted EBITDA within 3–5 years.

Inogen Stock Up 2.4%

Inogen stock opened at $6.36 on Tuesday. The company has a market cap of $173.20 million, a price-to-earnings ratio of -7.40 and a beta of 1.70. The firm’s fifty day moving average is $6.06 and its 200 day moving average is $6.91. Inogen has a 52-week low of $5.34 and a 52-week high of $9.13.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inogen in a report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $11.00.

Hedge Funds Weigh In On Inogen

A number of institutional investors and hedge funds have recently made changes to their positions in INGN. Panagora Asset Management Inc. raised its position in shares of Inogen by 48.4% during the 4th quarter. Panagora Asset Management Inc. now owns 48,195 shares of the medical technology company’s stock valued at $324,000 after buying an additional 15,715 shares in the last quarter. Rhumbline Advisers grew its position in Inogen by 7.0% in the second quarter. Rhumbline Advisers now owns 39,059 shares of the medical technology company’s stock worth $275,000 after acquiring an additional 2,561 shares in the last quarter. Tidal Investments LLC grew its position in Inogen by 38.8% in the second quarter. Tidal Investments LLC now owns 26,288 shares of the medical technology company’s stock worth $185,000 after acquiring an additional 7,348 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Inogen by 18.9% during the third quarter. Russell Investments Group Ltd. now owns 17,056 shares of the medical technology company’s stock worth $139,000 after acquiring an additional 2,717 shares during the last quarter. Finally, Brooklyn Investment Group bought a new stake in Inogen during the third quarter worth approximately $106,000. 89.94% of the stock is owned by hedge funds and other institutional investors.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.